BioN­Tech teams up with Fo­s­un Phar­ma to test Covid-19 mR­NA vac­cine in Chi­na — and scores $50M in­vest­ment

6 years ago
R&D
Coronavirus

Covid-19 roundup: Re­gen­eron, Sanofi launch coro­n­avirus pro­gram; NIH staffer tests pos­i­tive for coro­n­avirus, Mod­er­na ...

6 years ago
R&D
Coronavirus

Trump ad­min­is­tra­tion tries to lure Ger­man coro­n­avirus vac­cine mak­er to US — re­ports

6 years ago
R&D
Coronavirus

Bio­gen’s Covid-19 tal­ly breaks past the 100 mark, feed­ing the state to­tal as the con­ta­gion wreaks hav­oc

6 years ago
Coronavirus

Biotech en­tre­pre­neurs Arie Bellde­grun and Cedric Fran­cois test pos­i­tive for Covid-19 — and here's why they want you ...

6 years ago
People
Coronavirus

Cure­Vac’s In­g­mar Ho­err tells us why he re­turned to take on a pan­dem­ic; NGM los­es a pres­i­dent

6 years ago
Peer Review

Baven­cio from Mer­ck KGaA, Pfiz­er en­coun­ters yet an­oth­er tri­al set­back

6 years ago
R&D

The E100 biotech sur­vey: Ex­ecs are hun­ker­ing down for the pan­dem­ic, wor­ried about longterm fall­out — but ea­ger to ...

6 years ago
Special

Eli Lil­ly teams with an­ti­body up­start Ab­Cellera in coro­n­avirus hunt

6 years ago
R&D
Coronavirus

FDA of­fers Roche an emer­gency OK for coro­n­avirus test­ing tech — eas­ing a crit­i­cal log­jam

6 years ago
FDA+
Coronavirus

Taint­ed do­na­tions from stool bank reignite safe­ty con­cerns about poop trans­plants

6 years ago
R&D
FDA+

Part­nered with Gilead and Sanofi, pro­tein degra­da­tion spe­cial­ist Nurix bags $120M to chart its own clin­i­cal path

6 years ago
Financing

Bio­gen out­break con­tin­ues to spur new coro­n­avirus cas­es in Mass­a­chu­setts as health of­fi­cials strug­gle to keep up with ...

6 years ago
R&D
Coronavirus

A one-time biotech uni­corn gets slaugh­tered as lead pro­gram is scrapped, high­light­ing lin­ger­ing trou­ble

6 years ago
R&D
FDA+

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

6 years ago
News Briefing

Coro­n­avirus: WHO de­clares pan­dem­ic, EMA meet­ings go vir­tu­al

6 years ago
FDA+

At­las-backed Kymera grabs $102M as its pro­tein degra­da­tion tech­nol­o­gy heads in­to clin­ic

6 years ago
R&D

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for ...

6 years ago
People
R&D

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

6 years ago
Deals

Af­ter a year of big ad­vances, As­traZeneca CEO Pas­cal So­ri­ot takes home a ma­jor-league pay pack­age

6 years ago
People
Deals

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

6 years ago
People
Deals

A biotech tests Wall Street's roiled wa­ters and comes away with a $75M IPO haul

6 years ago
R&D

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

6 years ago
R&D

As the coro­n­avirus pan­dem­ic con­tin­ues to rat­tle the world, bio­phar­ma braces for a few new shocks to the sys­tem

6 years ago
Coronavirus
First page Previous page 853854855856857858859 Next page Last page
A service from the Financial Times